[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20161366A1 - Heterociclil-sulfonas sustituidas con heteroarilo - Google Patents

Heterociclil-sulfonas sustituidas con heteroarilo

Info

Publication number
PE20161366A1
PE20161366A1 PE2016002003A PE2016002003A PE20161366A1 PE 20161366 A1 PE20161366 A1 PE 20161366A1 PE 2016002003 A PE2016002003 A PE 2016002003A PE 2016002003 A PE2016002003 A PE 2016002003A PE 20161366 A1 PE20161366 A1 PE 20161366A1
Authority
PE
Peru
Prior art keywords
heteroaryl
substituted
heterociclyl
sulphones
compounds
Prior art date
Application number
PE2016002003A
Other languages
English (en)
Inventor
Kathy Mackenzie
Marc Rogers
Achim Kless
Stefan Schunk
Nils Damann
Florian Jakob
Melanie Reich
Michael Haurand
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20161366A1 publication Critical patent/PE20161366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se refiere a compuestos de formula I, donde: m es 1 o 2; n es 0 o 1; Y es un enlace o –C(R3)2-; R3 es H, alquilo C1-C6, entre otros; L es –[C(R4)2]x-(X)y-[C(R4)]z-; x es 0, 1 o 2; y es 0 o 1; z es 0 o 1; R4 es H, alquilo C1-C6, entre otros; X es O, S, S(O)2, entre otros; R1 es H, F, Cl, entre otros; R2 es H, F, Cl, entre otros; Ar1 y Ar2 son arilo o heteroarilo sustituidos. Son compuestos preferidos: 3-MetIlsulfonIl-5-[4-metIl-4-[[3-(trifluorometil)fenil]sulfonil]-tetrahidro-piran-2-il]- piridina; 5-Ciclopropil-2-[4-metil-4-[[3-(trifluorometil)fenil]sulfonil]-tetrahidro-piran-2-il]-piridina; entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son bloqueadores de los canales de calcio dependientes de voltaje, siendo utiles en el tratamiento y/o profilaxis del dolor
PE2016002003A 2014-04-14 2015-04-14 Heterociclil-sulfonas sustituidas con heteroarilo PE20161366A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14001346 2014-04-14

Publications (1)

Publication Number Publication Date
PE20161366A1 true PE20161366A1 (es) 2017-01-15

Family

ID=50486704

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016002003A PE20161366A1 (es) 2014-04-14 2015-04-14 Heterociclil-sulfonas sustituidas con heteroarilo

Country Status (16)

Country Link
US (2) US9879000B2 (es)
EP (2) EP3131894A1 (es)
JP (1) JP6673850B2 (es)
KR (1) KR20160144487A (es)
CN (1) CN106458956B (es)
AR (1) AR100073A1 (es)
AU (1) AU2015246387B2 (es)
BR (1) BR112016023860A2 (es)
CA (1) CA2945535A1 (es)
CL (1) CL2016002615A1 (es)
EA (1) EA032581B1 (es)
IL (1) IL248250A0 (es)
MX (1) MX2016013447A (es)
PE (1) PE20161366A1 (es)
TW (1) TW201620899A (es)
WO (1) WO2015158427A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP3131884A1 (en) * 2014-04-14 2017-02-22 Grünenthal GmbH Aryl substituted heterocyclyl sulfones
TW201726128A (zh) * 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
TW201718557A (zh) 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
AR108710A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos modulares de fxr (nr1h4)
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
PL4122464T3 (pl) 2017-03-28 2024-09-16 Gilead Sciences, Inc. Kombinacje terapeutyczne do leczenia chorób wątroby
WO2020116662A1 (ja) 2018-12-06 2020-06-11 第一三共株式会社 シクロアルカン−１，３−ジアミン誘導体
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
EP4045487A1 (en) * 2019-10-18 2022-08-24 Fmc Corporation Methods for the preparation of 5-bromo-2-(3-chloro-pyridin-2-yl)-2h-pyrazole-3-carboxylic acid
PL3976589T3 (pl) * 2019-10-18 2023-07-31 Fmc Corporation Sposoby wytwarzania kwasu 5-bromo-2-(3-chloropirydyn-2-ylo)-2H-pirazolo-3-karboksylowego

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
WO2007125398A2 (en) * 2006-04-27 2007-11-08 Pfizer Japan Inc. : sulfonamide compounds as antagonists of the n-type calcium channel
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
CN102762534A (zh) * 2009-09-18 2012-10-31 扎里卡斯药品有限公司 作为钙通道阻断剂的芳基砜衍生物
EP3131884A1 (en) * 2014-04-14 2017-02-22 Grünenthal GmbH Aryl substituted heterocyclyl sulfones
TW201726128A (zh) 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
TW201718557A (zh) 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸

Also Published As

Publication number Publication date
US20150291572A1 (en) 2015-10-15
EA201692049A1 (ru) 2017-04-28
MX2016013447A (es) 2017-01-18
BR112016023860A2 (pt) 2017-08-15
EP3495360A1 (en) 2019-06-12
CL2016002615A1 (es) 2017-04-28
US9879000B2 (en) 2018-01-30
KR20160144487A (ko) 2016-12-16
CA2945535A1 (en) 2015-10-22
IL248250A0 (en) 2016-11-30
EA032581B1 (ru) 2019-06-28
TW201620899A (zh) 2016-06-16
AU2015246387B2 (en) 2018-11-22
US9926302B2 (en) 2018-03-27
EP3131894A1 (en) 2017-02-22
JP6673850B2 (ja) 2020-03-25
CN106458956B (zh) 2019-06-14
WO2015158427A1 (en) 2015-10-22
JP2017511352A (ja) 2017-04-20
US20170121314A1 (en) 2017-05-04
AR100073A1 (es) 2016-09-07
CN106458956A (zh) 2017-02-22
AU2015246387A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
PE20161366A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo
CY1122542T1 (el) Νεα παραγωγα υδροξυεστερα, μια διεργασια για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1123645T1 (el) Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1124496T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
PE20171329A1 (es) Agentes inmunorreguladores
MX2021006804A (es) Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
CY1120325T1 (el) Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
EA201690135A1 (ru) Трициклические соединения бензоксаборола и их применение
PE20190913A1 (es) Derivados aromaticos de sulfonamida
CL2016002348A1 (es) Agonistas del receptor muscarínico
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
CY1118678T1 (el) Παραγωγα καρβοξαμιδιου χλωρο-πυραζινης χρησιμα για την θεραπευτικη αντιμετωπιση ασθενειων που ευνοουνται απο την ανεπαρκη ενυδατωση του βλεννογονου
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
EA201791304A1 (ru) Производные изохинолина для лечения вич
PE20191478A1 (es) Compuestos moduladores del receptor de hidorcarburos de arilo (ahr)
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
PE20191479A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
PE20161407A1 (es) Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide